Nasal IL-13 production identifies patients with late-phase allergic responses
Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved..
BACKGROUND: There is limited knowledge on how local cytokine secretion patterns after nasal allergen challenge correlate with clinical symptoms especially with regard to the "late allergic response," which occurs in approximately 40% to 50% of patients with allergy.
OBJECTIVE: We sought to characterize the immunologic and clinical nasal responses to birch pollen allergen challenge with a special focus on the late allergic response.
METHODS: In this randomized, double-blind, placebo-controlled trial, birch pollen-allergic participants were challenged with birch pollen extract (n = 20) or placebo (n = 10) on 3 consecutive days. On days 1 and 3, nasal secretions were collected at selected time points over a 24-hour time course for the measurement of 33 inflammatory mediators. Clinical responses were determined through subjective symptom scores and objective nasal airflow measurements.
RESULTS: Provoked participants had significantly greater clinical responses and showed significant increases in tryptase and the soluble IL-33 receptor serum stimulation 2 (sST2) in nasal secretions within minutes compared with the placebo group. Eight of 20 provoked participants displayed high IL-13 levels 2 to 8 hours after allergen provocation. This group also showed significant changes in clinical parameters, with a secondary drop in nasal airflow measured by peak nasal inspiratory flow and increased symptoms of nasal obstruction, which significantly differed from IL-13 nonresponders after 6 hours.
CONCLUSIONS: IL-13 response status correlates with clinical responses and type 2 cytokine responses in the late phase after allergen provocation.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:152 |
|---|---|
| Enthalten in: |
The Journal of allergy and clinical immunology - 152(2023), 5 vom: 01. Nov., Seite 1167-1178.e12 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Campion, Nicholas J [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 07.11.2023 Date Revised 13.11.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jaci.2023.06.026 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM360362370 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM360362370 | ||
| 003 | DE-627 | ||
| 005 | 20231226082845.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jaci.2023.06.026 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1201.xml |
| 035 | |a (DE-627)NLM360362370 | ||
| 035 | |a (NLM)37536510 | ||
| 035 | |a (PII)S0091-6749(23)00971-5 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Campion, Nicholas J |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Nasal IL-13 production identifies patients with late-phase allergic responses |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 07.11.2023 | ||
| 500 | |a Date Revised 13.11.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a BACKGROUND: There is limited knowledge on how local cytokine secretion patterns after nasal allergen challenge correlate with clinical symptoms especially with regard to the "late allergic response," which occurs in approximately 40% to 50% of patients with allergy | ||
| 520 | |a OBJECTIVE: We sought to characterize the immunologic and clinical nasal responses to birch pollen allergen challenge with a special focus on the late allergic response | ||
| 520 | |a METHODS: In this randomized, double-blind, placebo-controlled trial, birch pollen-allergic participants were challenged with birch pollen extract (n = 20) or placebo (n = 10) on 3 consecutive days. On days 1 and 3, nasal secretions were collected at selected time points over a 24-hour time course for the measurement of 33 inflammatory mediators. Clinical responses were determined through subjective symptom scores and objective nasal airflow measurements | ||
| 520 | |a RESULTS: Provoked participants had significantly greater clinical responses and showed significant increases in tryptase and the soluble IL-33 receptor serum stimulation 2 (sST2) in nasal secretions within minutes compared with the placebo group. Eight of 20 provoked participants displayed high IL-13 levels 2 to 8 hours after allergen provocation. This group also showed significant changes in clinical parameters, with a secondary drop in nasal airflow measured by peak nasal inspiratory flow and increased symptoms of nasal obstruction, which significantly differed from IL-13 nonresponders after 6 hours | ||
| 520 | |a CONCLUSIONS: IL-13 response status correlates with clinical responses and type 2 cytokine responses in the late phase after allergen provocation | ||
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Allergic rhinitis | |
| 650 | 4 | |a allergen | |
| 650 | 4 | |a biomarker | |
| 650 | 4 | |a birch pollen allergy | |
| 650 | 4 | |a cytokine responses | |
| 650 | 4 | |a late allergic response | |
| 650 | 4 | |a nasal allergen challenge | |
| 650 | 7 | |a Interleukin-13 |2 NLM | |
| 650 | 7 | |a Allergens |2 NLM | |
| 650 | 7 | |a Cytokines |2 NLM | |
| 700 | 1 | |a Villazala-Merino, Sergio |e verfasserin |4 aut | |
| 700 | 1 | |a Thwaites, Ryan S |e verfasserin |4 aut | |
| 700 | 1 | |a Stanek, Victoria |e verfasserin |4 aut | |
| 700 | 1 | |a Killick, Helen |e verfasserin |4 aut | |
| 700 | 1 | |a Pertsinidou, Eleftheria |e verfasserin |4 aut | |
| 700 | 1 | |a Zghaebi, Mohammed |e verfasserin |4 aut | |
| 700 | 1 | |a Toth, Josef |e verfasserin |4 aut | |
| 700 | 1 | |a Fröschl, Renate |e verfasserin |4 aut | |
| 700 | 1 | |a Perkmann, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Gangl, Katharina |e verfasserin |4 aut | |
| 700 | 1 | |a Schneider, Sven |e verfasserin |4 aut | |
| 700 | 1 | |a Ristl, Robin |e verfasserin |4 aut | |
| 700 | 1 | |a Scott, Ian C |e verfasserin |4 aut | |
| 700 | 1 | |a Cohen, Emma Suzanne |e verfasserin |4 aut | |
| 700 | 1 | |a Molin, Magnus |e verfasserin |4 aut | |
| 700 | 1 | |a Focke-Tejkl, Margit |e verfasserin |4 aut | |
| 700 | 1 | |a Regelsberger, Guenther |e verfasserin |4 aut | |
| 700 | 1 | |a Hansel, Trevor T |e verfasserin |4 aut | |
| 700 | 1 | |a Valenta, Rudolf |e verfasserin |4 aut | |
| 700 | 1 | |a Niederberger-Leppin, Verena |e verfasserin |4 aut | |
| 700 | 1 | |a Eckl-Dorna, Julia |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Journal of allergy and clinical immunology |d 1971 |g 152(2023), 5 vom: 01. Nov., Seite 1167-1178.e12 |w (DE-627)NLM000018449 |x 1097-6825 |7 nnns |
| 773 | 1 | 8 | |g volume:152 |g year:2023 |g number:5 |g day:01 |g month:11 |g pages:1167-1178.e12 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jaci.2023.06.026 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 152 |j 2023 |e 5 |b 01 |c 11 |h 1167-1178.e12 | ||